In non-small cell lung cancer (NSCLC) patients, testing for mutations in EGFR and KRAS, and EML4-anaplastic lymphoma kinase (ALK) gene rearrangements to select appropriately targeted therapy occurs on a routine basis. This evidence concerns the gene ALK and non-small cell lung carcinoma.